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Abstract The Gene Ontology (GO) is widely recognised as
the gold standard bioinformatics resource for summarizing
functional knowledge of gene products in a consistent and
computable, information-rich language. GO describes cellular
and organismal processes across all species, yet until now
there has been a considerable gene annotation deficit within
the neurological and immunological domains, both of which
are relevant to Parkinson’s disease. Here we introduce the
Parkinson’s disease GO Annotation Project, funded by
Parkinson’s UK and supported by the GO Consortium, which
is addressing this deficit by providing GO annotation to
Parkinson’s-relevant human gene products, principally
through expert literature curation. We discuss the steps taken
to prioritise proteins, publications and cellular processes for
annotation, examples of how GO annotations capture
Parkinson’s-relevant information, and the advantages that a
topic-focused annotation approach offers to users. Building
on the existing GO resource, this project collates a vast
amount of Parkinson’s-relevant literature into a set of high-
quality annotations to be utilized by the research community.
Keywords Annotation, database . Functional annotation .
Gene ontology . High-throughput analysis . Parkinson’s
disease
Introduction
Parkinson’s disease is the second most common neurodegen-
erative disorder after Alzheimer’s disease. An increased un-
derstanding of Parkinson’s disease has resulted from the iden-
tification and characterization of genes that cause or influence
the risk of developing this condition (Gasser et al. 2011).
Much of this knowledge has accumulated from ‘big data’
analyses, such as genome wide association (GWA) studies,
large-scale sequencing, proteomics and transcriptomic analy-
ses. Researchers have the increasingly complex task of eval-
uating these large datasets to detect relevant pathways and
regulatory networks, supported by resources including the
Gene Ontology (GO) (Gene Ontology Consortium 2015),
Reactome (Croft et al. 2014), KEGG (Kotera et al. 2012)
and protein interaction databases (Kerrien et al. 2012).
GO is widely recognised as the gold standard bioinformat-
ics resource for summarizing functional knowledge of gene
products across all kingdoms of life. GO contains three ontol-
ogies describing the molecular functions of a gene product,
the processes those actions are part of, and the cellular loca-
tion(s) of the gene product. GO terms are then associated with
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a gene product to create an ‘annotation’. GO annotations are
linked to an underlying reference, and include an evidence
code indicating the assay, algorithm or decision supporting
the annotation. A combination of manual and computational
approaches are taken to create these annotations, and include
summarising published research, inference by homology to
related annotated gene products, and mapping of annotations
from other biological resources such as Reactome, KEGG,
and InterPro (Mitchell et al. 2015).
GO is frequently used in the analysis of high-throughput
datasets, particularly for enrichment analyses where a gene-set
of interest is analysed for over-represented GO terms, as dem-
onstrated by Manzoni and colleagues in their examination of
the LRRK2 interactome (Manzoni et al. 2015). Meaningful
interpretation of such analyses depends on the quality of an-
notations that are available for the identified gene products,
and for Parkinson’s datasets this approach has been hampered
by insufficient functional annotation of many of the key af-
fected neurological and immunological pathways, both of
which are relevant to Parkinson’s disease (Holmans et al.
2013).
Results and Discussion
The Parkinson’s GO Annotation Initiative began in January
2014 to address the neurological and immunological annota-
tion deficit through the annotation of human proteins relevant
to the risk and progression of Parkinson’s disease, principally
by the expert curation of the biomedical literature. We aim to
comprehensively curate the role of 800 human proteins within
Parkinson’s-related processes by the end of 2016, and we are
well on our way to our annotation target with over 1000 pro-
teins already annotated, including 644 human proteins (as of
August 2015). We consider a protein to be comprehensively
annotated within a process when a curator is confident that the
annotations cover all aspect of the protein’s function within
that process. An overview of the full role of a protein within a
process is typically gained from reading recent reviews. In
practice, we have a limited time to annotate each protein,
consequently we usually stop annotating a well-researched
protein when annotation of additional papers leads to the re-
peated association of the same GO term to the protein.
Proteins described in only a small number of papers will be
annotated based on all available experimental evidence. Some
proteins will be comprehensively annotated across multiple
processes as we are taking a protein-based approach alongside
our topic-based approach, as described below. One such fully-
annotated protein is human PARK7 (DJ-1, Q99497), which
(as of 6th August 2015) has 226 annotations in total, 135 of
which were created by our project (Table 1 provides a selec-
tion of these annotations, note UniProtKB/Swiss-Prot protein
IDs are used throughout this article). Furthermore, 22 PARK7
annotations were assigned semi-automatically by the Ensembl
Compara pipeline (Cunningham et al. 2015) and eight of these
derive from our manual annotations to the orthologous mouse
Park7 entry (Q99LX0). Thus our project is increasing num-
bers of both manual and electronic annotations to improve
coverage.
Given the vast amount of literature available on
Parkinson’s disease, our first task was to define an annotation
priority set, and below we discuss the steps taken to prioritise
proteins, publications and cellular processes. Our high priority
protein set (https://www.ucl.ac.uk/functional-gene-
annotation/neurological/projects/high-priority-genes)
currently includes 48 proteins encoded either by familial
Parkinson’s disease genes or by candidate genes identified in
GWA studies. An extended priority list (http://www.ebi.ac.uk/
QuickGO/GProteinSet?id=ParkinsonsUK-UCL) also
contains proteins that interact with the high priority set, as
identified by IntAct (Porras et al. 2015), and proteins that
participate in Parkinson’s-relevant processes, as described
below.
A list of pathways and processes relevant to Parkinson’s
disease was assembled based on publications and discussions
with researchers. We took a process-based approach to anno-
tation alongside our protein-based strategy, to ensure that all
proteins within a Parkinson’s-relevant process are annotated,
and not just proteins with an already established link to the
disease. The process priority list includes mitochondrial pro-
cesses (such as mitophagy and mitochondrial fusion and fis-
sion), response to cellular stresses (including oxidative stress,
endoplasmic reticulum (ER) stress and nitrosative stress),Wnt
signaling, lysosomal pathways, dopamine metabolism, dopa-
mine transport, autophagy and synaptic transmission. We are
annotating all key players in these processes to capture multi-
ple aspects of Parkinson’s disease and allow examination of
the cellular networks that underlie the condition. We define a
key player as a protein that has been shown to be critical to a
process or regulation of a process, information we acquire
primarily through literature curation but also from attending
meetings in the field and communicating with researchers. In
addition, we are prioritising curation of Parkinson’s UK-
funded research articles. Furthermore, our priority lists remain
dynamic and are expanded to reflect new knowledge and sci-
entific advancements.
Thus far, we have manually curated nearly 300 publica-
tions, and generated over 4000 manual annotations, including
over 2700 annotations to human proteins (as of 6th August
2015). Our annotation focuses on human proteins, but given
the enormous knowledge contribution from model organism
data (Magen and Chesselet 2010; Pienaar et al. 2010), we also
annotate other organisms with a priority on mouse, rat and fly.
GO data is then transferred to orthologous human proteins
through the Ensembl-Compara pipeline or, in the absence of
automated methods, we manually transfer GO annotations
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between orthologs using the ISS (Inferred from Sequence or
structural Similarity) evidence code.
The role of a gene product can vary depending on its envi-
ronment or interactors, and in a GO Consortium-led approach
(Huntley et al. 2014), we extend the core GO annotation to
accommodate additional context, such as the cell type the
process occurs in, or the substrate of a catalytic activity. For
example, we capture that PML (P29590) and PARK7 (DJ-1,
Q99497) interact under conditions of oxidative stress (Kim
et a l . 2012) by extending the ‘prote in binding ’
(GO:0005515) annotation with the statement “happens_-
during cellular response to oxidative stress (GO:0034599)”.
By referencing the cell-type and anatomy ontologies (Bard
et al. 2005; Mungall et al. 2012) we annotate that
HERPUD1 (HERP, Q15011) is located in the ER of a neuron
in the substantia nigra (Slodzinski et al. 2009) by including
“part_ofCL:0000540, part_ofUBERON:0002038” in the an-
notation. One of the biggest benefits of providing this contex-
tual information is the ability to record the target of a protein’s
activity, e.g. capturing that murine Nfe2l2 (Nrf2, Q60795) is a
phosphorylation substrate of Eif2ak3 (Perk, Q9Z2B5) during
the Unfolded Protein Response (UPR) (Cullinan et al. 2003).
In this way we can link annotations together to provide the full
picture of a pathway or process, and in the future GO browsers
will support more sophisticated queries and analyses allowing
the extraction of, for example, all EIF2AK3 (PERK)
substrates.
To ensure annotations are of a high quality, we annotate to
GO Consortium guidelines that have been rigorously devel-
oped by trained curators. Internal and Consortium quality-
checking procedures, including peer-review, ensure that anno-
tations conform to these rules and are appropriate to the taxon
of the organism being annotated (Deegan née Clark et al.
2010). A long-term approach to maintaining annotation qual-
ity comes from the Phylogenetic Annotation Inference Tool
(PAINT) project (Gaudet et al. 2011) whereby annotations are
inferred through the phylogenetic tree. Curator input into the
annotation propagation ensures consistent annotation across
orthologs and highlights any potential anomalies or errors.
Our users and authors offer another layer of quality control;
we correspond with authors during curation to clarify ambi-
guities (for example the species origin of construct se-
quences). Furthermore, when paper annotation is complete,
we regularly notify the authors who can check that our anno-
tations accurately represent the published data.
Ontology Improvements
Ontology development goes hand-in-hand with annotation,
thus GO is being continually updated and expanded. A con-
siderable benefit of a topic-based curation approach is that
expert curators can apply their accumulated knowledge of a
biological research area to improve the ontology terms and
structure. To date, our project has contributed over 240 new
GO terms across all three ontology nodes including ‘CHOP-
C/EBP complex’ (GO:0036488), ‘ERAD pathway’
(GO:0036503), ‘chaperone-mediated autophagy ’
(GO:0061684), ‘L-dopa biosynthetic process’ (GO:1903185)
and ‘tyrosine 3-monooxygenase activator activity’
(GO:0036470), thereby enablingmore descriptive annotations
to be created. Using the UPR as an example; the endoplasmic
reticulum UPR is one pathway by which cells deal with un-
folded and misfolded proteins in the ER to restore the cell to
its resting state. ER stress has extensive links to Parkinson’s
disease (Varma and Sen 2015) and is therefore a project pri-
ority topic. To expand the ontology in this node, we created
new terms to represent the three main branches of the mam-
malian UPR (Fig. 1). Previously, the transcription factor ATF4
(P18848) had been annotated to ‘endoplasmic reticulum un-
folded protein response’ (GO:0030968). While this annota-
tion remains true, it does not capture how ATF4 fits into this
process. With our creation of new UPR terms, we were able to
associate the more descriptive term ‘PERK-mediated unfold-
ed protein response’ (GO:0036499) with ATF4. GO terms
mentioning gene products are the exception but where they
exist, the name reflects the gene or protein name most com-
monly used in the research field (e.g. PERK) and is designed
to be species-neutral wherever possible. Synonyms including
species-specific nomenclature (e.g. EIF2AK3) are added
when required to capture additional information and improve
search capabilities. Ontology construction requires consider-
able curator input, consequently we have created over 180 of
our new GO terms using the TermGenie tool (Dietze et al.
2014), which enables formally specified design patterns and
templates to appropriately place and define each new term.
Call for Community Contributions
To make the greatest impact in the area of Parkinson’s dis-
ease, it is important that we consult experts in the field to
ensure our GO annotations and terms are accurately captur-
ing current knowledge. Thus we have established a scien-
tific advisory panel for consultation and we interact with
researchers and authors during curation, as described
above. When curating a topic, we also refer to Reactome
(Croft et al. 2014) and the Parkinson’s disease map (Fujita
et al. 2014) to align our efforts with these manually-curated
resources of cellular pathways and Parkinson’s-related
mechanisms, respectively. We have held discussions with
the scientists responsible for these resources to standardise
annotations and Parkinson’s-related GO terms, and we plan
to create further reciprocal links as our project progresses.
We welcome feedback from the community, and there are
many additional ways in which researchers can be involved
with the project, or be kept informed about developments.
Please contact us (goannotation@ucl.ac.uk) to:
Neuroinform
i) Subscribe to our quarterly newsletter.
ii) Extend our gene priority lists by supplying us with de-
tails of key proteins.
iii) Suggest gene annotations that are currently missing, or
literature that requires curation.
Furthermore, our project progress can be followed on our
Twitter account (@UCLgene) and the go-friends email list
(http://geneontology.org/page/go-mailing-lists) can be
subscribed to stay informed about all GO projects.
Conclusions
With this project we are providing an integrated, comprehen-
sive set of annotations to describe proteins implicated, or pre-
dicted to play a role, in Parkinson’s disease. Our project will
specifically build on the efforts of the Toronto Alzheimer’s
disease annotation project (Patel et al. 2015), which is focused
on using GO to identify proteins involved in Alzheimer’s
disease through imaging genetics studies. To enhance the
functionality of GO in their analyses, they created over 30
new relevant GO terms, and nearly 200 GO annotations to
15 human proteins (http://www.ebi.ac.uk/QuickGO/
GAnnotation?tax=9606&source=Alzheimers_University_of_
Toronto) with some notable overlap in prioritized proteins
(e.g. Tau). There are a growing number of focused GO
annotat ion projects , such as those cover ing the
cardiovascular and transcription domains (Alam-Faruque
et al. 2011; Tripathi et al. 2013), and these combined efforts
are, together with the major GO Consortiummembers groups,
improving the breadth and depth of the GO annotations
available.
Previous GO Consortium projects have demonstrated the
benefit of a topic-based annotation approach with notable im-
provements of the interpretation of relevant datasets (Alam-
Faruque et al. 2014), and we envisage that our project will
have a similar impact on the analysis of many neurobiological
Fig. 1 Representation of the Unfolded Protein Response (UPR) in the
Gene Ontology. To better represent the endoplasmic reticulum UPR
(GO:0030968: in green) within the Gene Ontology, we created new terms
(denoted by red stars) for ‘IRE1-mediated unfolded protein response’
(GO:0036498), ‘PERK-mediated unfolded protein response’
(GO:0036499) and ‘ATF6-mediated unfolded protein response’
(GO:0036500), covering the three main branches of the mammalian
UPR. GO:0070055 (in yellow) describes IRE1-mediated non-
spliceosomal cleavage of the XBP1 mRNA in mammals and Ire1p-
mediated cleavage of the HAC1 mRNA in yeast. Additional terms exist
in this node but are not shown for conciseness. Black arrows denote is_a
relationships between terms and blue arrows denote part_of relationships
between terms. Image adapted from QuickGO
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datasets, not only those related to Parkinson’s disease. Many
neurodegenerative diseases share underlying cellular and mo-
lecular mechanisms, and the majority of the processes we
have prioritised for annotation are relevant to other diseases.
Disruption of the autophagy machinery, for example, can lead
to a number of neurological disorders (Nah et al. 2015) in-
cluding Parkinson’s disease, Alzheimer ’s disease,
Huntington’s disease, Amyotrophic lateral sclerosis (ALS)
and Multiple sclerosis, and beyond neurodegeneration au-
tophagy has been linked to cancer, aging, liver and muscle
disorders, and infection by pathogens (Shintani and
Klionsky 2004). Dys-regulated Wnt signalling has also been
suggested to underlie many neurological conditions including
Alzheimer’s disease (Sadigh-Eteghad et al. 2015), autism and
schizophrenia (reviewed in Berwick and Harvey 2014), and
abnormal CDK5 signaling has a role in the pathogenesis of
various neurodegenerative disorders including Parkinson’s
and Alzheimer’s diseases, disrupting proteins including α-
synuclein (ASN) and β-amyloid peptide (Aβ) (Wilkaniec
et al. 2015). Lysosomal transport was prioritised for curation
based on its relevance to Parkinson’s disease but it has wider
implications, with lysosomal storage disorders and neurode-
generative disorders sharing a dysfunctional cellular transport
network (Boland and Platt 2015).
Stress-insult is a common theme across human health,
with the antioxidant PARK7 (DJ-1) playing a central role
in protecting against oxidative stress in cancer, cardiovas-
cular disease and neurodegeneration (Chan and Chan
2015). ER-stress and particularly ERAD is linked to more
than 60 diseases (Guerriero and Brodsky 2012; Yoshida
2007), including Cystic fibrosis (Kerbiriou et al. 2007)
and bipolar disorder (Pfaffenseller et al. 2014). Our prior-
itized proteins are also implicated in additional disorders;
a search in OMIM (http://omim.org/) reveals that
mutations in MAPT encoding the microtubule-associated
protein Tau are linked to a number of neurological disor-
ders including Frontotemporal dement ia (FTD),
Progressive supranuclear palsy 1 (PSNP1), and of course
Alzheimer’s disease.
These examples are by no means exhaustive but aim to
demonstrate how our improved annotations and additions
to the GO structure will feed into the interpretation of
datasets across a wide range of diseases, not only within
the neurodegenerative spectrum, but also extending to
other areas of health and disease. More manual annota-
tions will mean that users will get more meaningful func-
tional data analysis, with potentially more specific terms
being significantly enriched in transcriptomic or proteo-
mic studies. Furthermore, GO is already being used to
improve GWAS identification of risk SNPs (Holmans
et al. 2013), and improving GO for Parkinson’s disease is
likely to further aid this approach, for a range of neurodegen-
erative diseases.
Combining GO with external resources further enhances
its applications: Cytoscape (Shannon et al. 2003) enables
our improved GO annotations to be combined with interac-
tion data captured by IntAct, so researchers can visualize
and manipulate protein interaction networks overlaid with
significantly enriched GO processes. These networks may
be used to predict ‘hubs’, key positions at which the whole
network may be perturbed, and thus inform future research.
Tools are currently being developed which will allow users
to create complex queries based on the cross-links between
GO and the chemical ontology ChEBI (Hill et al. 2013;
Mungall et al. 2011), and the Parkinson’s-relevant annota-
tions. Thus it will be possible to identify all gene products
involved in dopamine processes in unrelated parts of the
GO graph, such as dopamine transport, dopamine metabo-
lism and dopamine binding, or all proteins involved in the
metabolism of dopaminergic agents. We hope that our re-
source will benefit neurobiology researchers and scientists,
and we encourage you to contact us with your questions or
suggestions.
Information Sharing Statement
All of the annotations associated with our prioritised
Parkinson’s-relevant proteins are freely available for viewing
or download in QuickGO (http://www.ebi.ac.uk/QuickGO/,
RRID:SCR_004608) (Binns et al. 2009) using the ‘Gene
Product ID’ filter ‘ParkinsonsUK-UCL’ or in the GO
Consortium browser, AmiGO (http://amigo.geneontology.org/,
RRID:SCR_002143) (Carbon et al. 2009). In addition, these
annotations and ontologies are uploaded to major biological
knowledgebases such as Ensembl, NCBIGene and UniProtKB,
and are available for download and local installation via ftp sites.
Users can perform enrichment analysis on neurological
datasets using a number of GO-supported enrichment tools
(http://geneontology.org/page/go-enrichment-analysis).
Acknowledgments We would like to thank the GO editorial team for
useful ontology discussions and implementation of many ontology
changes. We are very grateful to Heiko Dietze and other contributors to
the TermGenie tool. PD, RF, JH, MM, RL and TS are funded by
Parkinson’s UK, grant G-1307. PD, RF and RL are also supported by
the National Institute for Health Research University College London
Hospitals Biomedical Research. RL received additional support as a Brit-
ish Heart Foundation (BHF) chair scholar and MM, RL and TS received
funding by BHF grant RG/13/5/30112. TS is also supported by National
Institute of Health NIH/NHGRI grant U41HG002273. JH is also support-
ed by the M.J. Fox Pritzker Prize, and a Wellcome Trust/MRC Joint Call
in Neurodegeneration award (WT089698) to the UK Parkinson’s Disease
Consortium (UKPDC).
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no conflict of
interest.
Neuroinform
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Alam-Faruque, Y., Huntley, R. P., Khodiyar, V. K., Camon, E. B.,
Dimmer, E. C., Sawford, T., et al. (2011). The impact of focused
gene ontology curation of specific mammalian systems. PLoS One,
6(12), e27541. doi:10.1371/journal.pone.0027541.
Alam-Faruque, Y., Hill, D. P., Dimmer, E. C., Harris, M. A., Foulger, R.
E., Tweedie, S., et al. (2014). Representing kidney development
using the gene ontology. PLoS One, 9(6), e99864. doi:10.1371/
journal.pone.0099864.
Bard, J., Rhee, S. Y., & Ashburner, M. (2005). An ontology for cell types.
Genome Biology, 6(2), R21. doi:10.1186/gb-2005-6-2-r21.
Berwick, D. C., & Harvey, K. (2014). The regulation and deregulation of
Wnt signaling by PARK genes in health and disease. Journal of
Molecular Cell Biology, 6(1), 3–12. doi:10.1093/jmcb/mjt037.
Binns, D., Dimmer, E., Huntley, R., Barrell, D., O’Donovan, C., &
Apweiler, R. (2009). QuickGO: a web-based tool for gene ontology
searching. Bioinformatics (Oxford, England), 25(22), 3045–3046.
doi:10.1093/bioinformatics/btp536.
Boland, B., & Platt, F. M. (2015). Bridging the age spectrum of neurode-
generative storage diseases. Best practice & research. Clinical
Endocrinology & Metabolism, 29(2), 127–143. doi:10.1016/j.
beem.2014.08.009.
Carbon, S., Ireland, A., Mungall, C. J., Shu, S., Marshall, B., Lewis, S.,
et al. (2009). AmiGO: online access to ontology and annotation data.
Bioinformatics (Oxford, England), 25(2), 288–289. doi:10.1093/
bioinformatics/btn615.
Chan, J. Y. H., & Chan, S. H. H. (2015). Activation of endogenous
antioxidants as a common therapeutic strategy against cancer, neu-
rodegeneration and cardiovascular diseases: a lesson learnt fromDJ-
1. Pharmacology & Therapeutics. doi:10.1016/j.pharmthera.2015.
09.005.
Croft, D., Mundo, A. F., Haw, R., Milacic, M., Weiser, J., Wu, G., et al.
(2014). The reactome pathway knowledgebase. Nucleic Acids
Research, 42(Database issue), D472–D477. doi:10.1093/nar/
gkt1102.
Cullinan, S. B., Zhang, D., Hannink, M., Arvisais, E., Kaufman, R. J., &
Diehl, J. A. (2003). Nrf2 is a direct PERK substrate and effector of
PERK-dependent cell survival. Molecular and Cellular Biology,
23(20), 7198–7209.
Cunningham, F., Amode, M. R., Barrell, D., Beal, K., Billis, K., Brent, S.,
et al. (2015). Ensembl 2015. Nucleic Acids Research, 43(Database
issue), D662–D669. doi:10.1093/nar/gku1010.
Deegan née Clark, J. I., Dimmer, E. C., & Mungall, C. J. (2010).
Formalization of taxon-based constraints to detect inconsistencies
in annotation and ontology development. BMC Bioinformatics, 11,
530. doi:10.1186/1471-2105-11-530.
Dietze, H., Berardini, T. Z., Foulger, R. E., Hill, D. P., Lomax, J., Osumi-
Sutherland, D., et al. (2014). TermGenie - a web-application for
pattern-based ontology class generation. Journal of Biomedical
Semantics, 5, 48. doi:10.1186/2041-1480-5-48.
Fujita, K. A., Ostaszewski, M., Matsuoka, Y., Ghosh, S., Glaab, E.,
Trefois, C., et al. (2014). Integrating pathways of Parkinson’s dis-
ease in a molecular interactionmap.Molecular Neurobiology, 49(1),
88–102. doi:10.1007/s12035-013-8489-4.
Gasser, T., Hardy, J., & Mizuno, Y. (2011). Milestones in PD genetics.
Movement Disorders: Official Journal of the Movement Disorder
Society, 26(6), 1042–1048. doi:10.1002/mds.23637.
Gaudet, P., Livstone, M. S., Lewis, S. E., & Thomas, P. D. (2011).
Phylogenetic-based propagation of functional annotations within
the gene ontology consortium. Briefings in Bioinformatics, 12(5),
449–462. doi:10.1093/bib/bbr042.
Gene Ontology Consortium (2015). Gene ontology consortium: going
forward. Nucleic Acids Research, 43(Database issue), D1049–
D1056. doi:10.1093/nar/gku1179.
Guerriero, C. J., & Brodsky, J. L. (2012). The delicate balance between
secreted protein folding and endoplasmic reticulum-associated deg-
radation in human physiology. Physiological Reviews, 92(2), 537–
576. doi:10.1152/physrev.00027.2011.
Hill, D. P., Adams, N., Bada, M., Batchelor, C., Berardini, T. Z., Dietze,
H., et al. (2013). Dovetailing biology and chemistry: integrating the
gene ontology with the ChEBI chemical ontology. BMC Genomics,
14, 513. doi:10.1186/1471-2164-14-513.
Holmans, P., Moskvina, V., Jones, L., Sharma, M., International
Parkinson’s Disease Genomics Consortium, Vedernikov, A., et al.
(2013). A pathway-based analysis provides additional support for an
immune-related genetic susceptibility to Parkinson’s disease.
Human Molecular Genetics, 22(5), 1039–1049. doi:10.1093/hmg/
dds492.
Huntley, R. P., Harris, M. A., Alam-Faruque, Y., Blake, J. A., Carbon, S.,
Dietze, H., et al. (2014). A method for increasing expressivity of
gene ontology annotations using a compositional approach. BMC
Bioinformatics, 15, 155. doi:10.1186/1471-2105-15-155.
Kerbiriou,M., Le Drévo,M.-A., Férec, C., & Trouvé, P. (2007). Coupling
cystic fibrosis to endoplasmic reticulum stress: differential role of
Grp78 and ATF6. Biochimica Et Biophysica Acta, 1772(11–12),
1236–1249. doi:10.1016/j.bbadis.2007.10.004.
Kerrien, S., Aranda, B., Breuza, L., Bridge, A., Broackes-Carter, F.,
Chen, C., et al. (2012). The IntAct molecular interaction database
in 2012. Nucleic Acids Research, 40(Database issue), D841–D846.
doi:10.1093/nar/gkr1088.
Kim, S.-J., Park, Y.-J., Hwang, I.-Y., Youdim, M. B. H., Park, K.-S., &
Oh, Y. J. (2012). Nuclear translocation of DJ-1 during oxidative
stress-induced neuronal cell death. Free Radical Biology &
Medicine, 53(4), 936–950. doi:10.1016/j.freeradbiomed.2012.05.
035.
Kotera, M., Hirakawa, M., Tokimatsu, T., Goto, S., & Kanehisa, M.
(2012). The KEGG databases and tools facilitating omics analysis:
latest developments involving human diseases and pharmaceuticals.
Methods in Molecular Biology (Clifton, N.J.), 802, 19–39. doi:10.
1007/978-1-61779-400-1_2.
Magen, I., & Chesselet, M.-F. (2010). Genetic mouse models of
Parkinson’s disease the state of the art. Progress in Brain
Research, 184, 53–87. doi:10.1016/S0079-6123(10)84004-X.
Manzoni, C., Denny, P., Lovering, R. C., & Lewis, P. A. (2015).
Computational analysis of the LRRK2 interactome. PeerJ, 3,
e778. doi:10.7717/peerj.778.
Mitchell, A., Chang, H.-Y., Daugherty, L., Fraser, M., Hunter, S., Lopez,
R., et al. (2015). The InterPro protein families database: the classi-
fication resource after 15 years. Nucleic Acids Research,
43(Database issue), D213–D221. doi:10.1093/nar/gku1243.
Mungall, C. J., Bada, M., Berardini, T. Z., Deegan, J., Ireland, A., Harris,
M. A., et al. (2011). Cross-product extensions of the gene ontology.
Journal of Biomedical Informatics, 44(1), 80–86. doi:10.1016/j.jbi.
2010.02.002.
Mungall, C. J., Torniai, C., Gkoutos, G. V., Lewis, S. E., & Haendel, M.
A. (2012). Uberon, an integrative multi-species anatomy ontology.
Genome Biology, 13(1), R5. doi:10.1186/gb-2012-13-1-r5.
Nah, J., Yuan, J., & Jung, Y.-K. (2015). Autophagy in neurodegenerative
diseases: from mechanism to therapeutic approach. Molecules and
Cells, 38(5), 381–389. doi:10.14348/molcells.2015.0034.
Neuroinform
Patel, S., Park, M. T. M., Chakravarty, M. M., & Knight, J. (2015). Novel
bioinformatics approach to investigate quantitative phenotype-
genotype associat ions in neuroimaging studies (No.
biorxiv;015065v1). http://biorxiv.org/lookup/doi/10.1101/015065.
Accessed 5 November 2015
Pfaffenseller, B.,Wollenhaupt-Aguiar, B., Fries, G. R., Colpo, G. D., Burque,
R. K., Bristot, G., et al. (2014). Impaired endoplasmic reticulum stress
response in bipolar disorder: cellular evidence of illness progression.
The International Journal of Neuropsychopharmacology/Official
Sc ien t i f i c Journal o f the Col leg ium In terna t iona le
Neuropsychopharmacologicum (CINP), 17(9), 1453–1463. doi:10.
1017/S1461145714000443.
Pienaar, I. S., Götz, J., & Feany, M. B. (2010). Parkinson’s disease:
insights from non-traditional model organisms. Progress in
Neurobiology, 92(4), 558–571. doi:10.1016/j.pneurobio.2010.09.
001.
Porras, P., Duesbury, M., Fabregat, A., Ueffing, M., Orchard, S.,
Gloeckner, C. J., & Hermjakob, H. (2015). A visual review of the
interactome of LRRK2: using deep-curated molecular interaction
data to represent biology. Proteomics, 15(8), 1390–1404. doi:10.
1002/pmic.201400390.
Sadigh-Eteghad, S., Askari-Nejad, M. S., Mahmoudi, J., & Majdi, A.
(2015). Cargo trafficking in Alzheimer’s disease: the possible role
of retromer. Neurological Sciences: Official Journal of the Italian
Neurological Society and of the Italian Society of Clinical
Neurophysiology. doi:10.1007/s10072-015-2399-3.
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T.,
Ramage, D., et al. (2003). Cytoscape: a software environment
for integrated models of biomolecular interaction networks.
Genome Research, 13(11), 2498–2504. doi:10.1101/gr.
1239303.
Shintani, T., & Klionsky, D. J. (2004). Autophagy in health and disease: a
double-edged sword. Science (New York, N.Y.), 306(5698), 990–
995. doi:10.1126/science.1099993.
Slodzinski, H., Moran, L. B., Michael, G. J., Wang, B., Novoselov, S.,
Cheetham, M. E., et al. (2009). Homocysteine-induced endoplasmic
reticulum protein (herp) is up-regulated in parkinsonian substantia
nigra and present in the core of Lewy bodies. Clinical
Neuropathology, 28(5), 333–343.
Tripathi, S., Christie, K. R., Balakrishnan, R., Huntley, R., Hill, D. P.,
Thommesen, L., et al. (2013). Gene Ontology annotation of
sequence-specific DNA binding transcription factors: setting the
stage for a large-scale curation effort. Database: The Journal of
Biological Databases and Curation, 2013 bat062. doi:10.1093/
database/bat062.
Varma, D., & Sen, D. (2015). Role of the unfolded protein response in the
pathogenesis of Parkinson’s disease. Acta Neurobiologiae
Experimentalis, 75(1), 1–26.
Wilkaniec, A., Czapski, G. A., & Adamczyk, A. (2015). CDK5 at cross-
roads of protein oligomerization in neurodegenerative diseases: facts
and hypotheses. Journal of Neurochemistry. doi:10.1111/jnc.13365.
Yoshida, H. (2007). ER stress and diseases. The FEBS Journal, 274(3),
630–658. doi:10.1111/j.1742-4658.2007.05639.x.
Neuroinform
